(PharmaNewsWire.Com, April 13, 2020 ) Market Overview The Global Dravetsyndrometherapeutics Market is expected to grow at a high CAGR during the forecasting period (2019-2026). Dravet syndrome is an epilepsy syndrome that begins in early childhood with a spectrum of symptoms ranging from mild to severe. It can occur due to mutations in SCN1A gene or from family. According to the National Center for Advancing Translational Sciences, it is reported that 85% of Dravet syndrome cases originated due to a mutation in the SCN1A gene and, 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists. Market Dynamics Many factors such as the rising R&D expenditure, increasing government assistance, rising healthcare expenditure in the developed countries, are the few factors propelling the growth of the global Dravet syndrome market. Additionally, development of new drugs and therapies by prominent manufacturers to have diversified product portfolio is boosting the global Dravet syndrome therapeutics market. For instance, in 2017, Biscayne Neurotherapeutics, Inc., received approval from the U.S. FDA for its compound BIS-001 indicated for the treatment of Dravet syndrome. Similarly, in 2017, Takeda Pharmaceutical Company collaborated with Ovid for development and commercialization of TAK-935/OV935 for the treatment of developmental and epileptic encephalopathy. However, side effects of drugs and other therapeutic agents, lack of awareness among people are the major factors hampering the global Dravet syndrome therapeutics market. According to the National Center for Biotechnology Information (NCBI), in 2015, the Dravet syndrome affects only around 1 out of 15,700 individuals in the U.S. Market Segmentation Based on the treatment type the global syndrome therapeutics market is broadly segmented into Anticonvulsant therapies, vagus nerve stimulation, Ketogenic diet. Anticonvulsant therapies segment accounted for major market share in 2018 and is expected to grow at a high CAGR over the forecast period. Anticonvulsant therapies are commonly known as seizure drugs which include clobazam, Topiramate, valproic acid, stiripentol, Levetiracetam and others. They are used to provide symptomatic only and have not been demonstrated to alter the course of epilepsy. They reduce seizure frequency by suppressing neuronal excitability via various molecular targets in the synapse. Additionally, new drug developments in this segment is expected to drive the global market. For instance, in 2018, Epidiolex (cannabidiol or CBD) by GW Research Ltd. was approved to treat seizures associated with Dravet syndrome in patients two years of age and older. This is the first FDA-approved cannabinoid product to treat Dravet syndrome. Geographical Analysis The global Dravet Syndrome Therapeutics market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America region accounted for major market share in 2018 in the global Dravet syndrome treatment market. It is owing to the growth initiatives and funding by various organizations to support the development of new treatment for Dravet syndrome. For instance, in 2017, Dravet Syndrome Foundation, funded an amount of US$ 3,600,000 for the development of new treatment methods for this disorder. During the forecast period (2019-2026) Asia Pacific region expected to grow at a significant rate, owing to a huge patient pool. Further developing healthcare technology & rising healthcare expenditure in various Asia Pacific countries such as China, India, and Australia. According to Australian Institutes of Health and Welfare (AIHW), Australia spent $180.7 billion on health in 201617 i.e. more than $7,400 per person which grew by 4.7% from 201516. Competitive Analysis Significant players of the global Dravet syndrome therapeutics market are Epygenix Therapeutics, Inc., GW Pharmaceuticals Plc., Ovid Therapeutics, Takeda Pharmaceutical Company Ltd, OPKO Health Inc., Zogenix, Inc, Biocodex S.A., PTC Therapeutics, Inc., Biscayne Neurotherapeutics, Inc., and others. The diversified product portfolio is the major factor that is responsible for strengthening the position of these companies in the market. Also, they have been adopting key strategies, such as new product developments, acquisitions, and expansions, to increase their share in the Dravet syndrome therapeutics market. For instance In February 2018, Zogenix Inc. received approval for its Phase III drug ZX-008 for seizures associated with Dravet Syndrome from FDA. In 2018, Dicomit (stiripentol) by Biocodex was approved for the treatment of seizures associated with Dravet syndrome. In 2017, Epygenix Therapeutics, Inc., a biopharmaceutical company, got approval for its EPX-300 drug, indicated for the treatment of the Dravet syndrome from FDA. In 2017, Ovid Therapeutics (the U.S.) got orphan drug designation from FDA for its product, TAK-935/OV935. Download Free Sample: https://www.datamintelligence.com/download-sample/dravet-syndrome-therapeutics-market Why Purchase the Report? Visualize the composition of the dravet syndrome therapeutics market across each indication, in terms of Treatment Type and distribution channel options, highlighting the key commercial assets and players. Identify commercial opportunities in Dravet syndrome therapeutics market by analyzing trends and co-development deals. Excel data sheet with thousands of data points of the Dravet syndrome therapeutics market - level 4/5 segmentation. A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. Product mapping in excel for the key products of all major market players Target Audience: Equipment Suppliers/ Buyers Service Providers/ Buyers Industry Investors/Investment Bankers Education & Research Institutes Research Professionals Emerging Companies Manufacturers
About Us DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information: Sai Kiran Sales Manager at DataM Intelligence Email: info@datamintelligence.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
